TABLE 1.

Anti-hepatic fibrosis drugs related to inhibiting inflammation and protecting hepatocyte cells.

Anti-fibrotic mechanism	Agent	Target	Research state	NCT number	References
Anti-inflammatory	Met-CCL5	CCR5	Preclinical study	–	Berres et al., 2010
	Cenicriviroc	CCR2/5	Phase 3	NCT03028740	Friedman et al., 2016, 2018; Tacke, 2018
	Belapectin	Gal-3	Phase 3	NCT02462967	Harrison et al., 2016; Chalasani et al., 2020
	Aspirin	TLR/NF-kB	Preclinical study	–	Liu et al., 2020
	GS-0976	ACC	Phase 3	NCT02548351	Loomba et al., 2018a
	WZ66	ACC1/2	Preclinical study	–	Gao et al., 2020
	Liraglutide	GLP-1	Phase 3	NCT02654665	Armstrong et al., 2016
	Resmetirom	THR-β	Phase 2	NCT02912260	Harrison et al., 2019
Inhibition of oxidative stress	Oroxylin A	ROS	Preclinical study	–	Shen et al., 2020
	Methyl ferulic acid	NOX4/ROS	Preclinical study	–	Cheng et al., 2019
	GKT137831	NOX1/4	Phase 2	NCT03226067	Aoyama et al., 2012; Jiang et al., 2012
	Losartan	AngII	Phase 4	NCT00298714	Colmenero et al., 2009
Inhibition of hepatocyte apoptosis	VX-166	Pan-caspase	Preclinical study	–	Witek et al., 2009
	Emricasan	Pan-caspase	Phase 2	NCT02138253	Barreyro et al., 2015; Frenette et al., 2019; Gracia-Sancho et al., 2019; Harrison et al., 2020a
	Pentoxifylline	TNF-α	Phase 2	NCT02283710	Toda et al., 2009
	β-elemene	TNF-α	Preclinical study	–	Liu et al., 2011
	Selonsertib	ASK1	Phase 3	NCT03053050; NCT03053063	Loomba et al., 2018b; Harrison et al., 2020c; Yoon et al., 2020